• A V Bazhenov, G M Galstyan, E N Parovichnikova, V V Troitskaya, L A Kuzmina, Z T Fidarova, E O Gribanova, S A Makhinya, O A Latyshkevich, U A Chabaeva, S M Kulikov, and V G Savchenko.
• National Research Center for Hematology.
• Terapevt Arkh. 2019 Jul 15; 91 (7): 14-24.

AimRemission induction can be associate, with the life threatening complications and transfer to ICU of de novo acute myeloid leukemia (AML) patients (pts). We evaluate influence of transfer to ICU and life threatening complication on early mortality and long - tram survival of de novo AML pts.Materials And MethodsRetrospective study. All de novo AML pts younger than 60 years old admitted in the National Research Center for Hematology from 2013 to 2016 years were enrolled in the study. Patients were divided into 2 groups: pts who were required ICU admission during remission induction (ICU-pts) and pts who did not require ICU admission and received chemotherapy only in hematology ward (non-ICU pts). The reasons for ICU admissions and results of life support were analyzed. Overall survival (OS) were assessed by the Kaplan-Meier method, long rank value p.

10 keywords...

hide…